Enzo Biochem (ENZ) Osake Kurssi
Enzo Biochem Kurssi
Viimeisten 19 vuoden aikana Enzo Biochemn liikevaihto kasvoi 18,4 % vuodessa ja ylsi 992,90 M USD:een. Osakekohtainen tulos on laskenut 30,0 % vuodessa viimeisten 5 vuoden aikana. Enzo Biochemn nettomarginaali −0,8 % on laskenut verrattuna 6,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 18,20 %.
Enzo Biochem osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Enzo Biochem liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Enzo Biochem -osakkeesta
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.
The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.
Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.
Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.
Enzo Biochem Inc is primarily present in the United States.
Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.
5 analyytikkoa arvioi tällä hetkellä Enzo Biochem-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Enzo Biochem-yhtiöltä 107,03 M USD liikevaihtoa ja −0,07 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Enzo Biochem-osake noteerataan hintaan 0,50 EUR (0,55 USD).
Enzo Biochem-osake (ENZ) on listattuna 6 pörssissä, muun muassa: NYSE (ENZ), London (0IHV.L), SIX (Zürich) (EZB.SW), Frankfurt (EZB.F), München (EZB.MU), Düsseldorf (EZB.DU).
Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.
odotettu liikevaihto Enzo Biochem on 107,03 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Enzo Biochem on −9,72 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Enzo Biochem:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,85. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Enzo Biochem-osakkeen arvostusta.
Enzo Biochem:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,71. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Enzo Biochem-osakkeen arvostuskennuslukuna.
Enzo Biochem:n Eulpool-laatuscore on 6/10.
Enzo Biochem:n ISIN on US2941001024. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Enzo Biochem:n WKN on 865607. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Enzo Biochem:n ticker on ENZ. Tämä pörssinoteeraus käytetään Enzo Biochem-osakkeiden kauppaan pörssissä.
Enzo Biochem osake
Enzo Biochem vertaisryhmä
Enzo Biochem Ticker
Enzo Biochem FIGI
Kaikki tunnusluvut ja syvällinen analyysi Enzo Biochem:sta
Meidän osakeanalyysimme Enzo Biochem-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Enzo Biochem:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: